SOURCE: Bioheart, Inc.

Bioheart, Inc.

March 21, 2013 08:09 ET

Bioheart Secures Investment and Announces Immediate Launching of ANGEL Trial

SUNRISE, FL--(Marketwire - Mar 21, 2013) - Bioheart, Inc. (OTCQB: BHRT) has announced that it has secured the necessary funding for the ANGEL trial. This trial will initiate in Mexico at the Hospital Angeles with the Regenerative Medicine Institute (RMI). The phase one trial will test the safety and efficacy of LipiCell™ (adipose derived stem cells) in congestive heart failure patients. The first cohort of five patients will be completed and analyzed to help establish a safety profile and preliminary efficacy.

"The facilities at Hospital Angeles and RMI are top notch and we are excited to move the ANGEL trial forward. We anticipate quick enrollment with follow up time points at 3, 6 and 12 months," said Kristin Comella, Chief Science Officer of Bioheart.

Bioheart's cell therapy products address an unmet need in the cardiac market by providing true regenerative medicine where the MyoCell® product line may regenerate muscle in areas of scar tissue and the LipiCell® product may help reduce inflammation and promote the growth of new blood vessels. Bioheart intends to complete a portion of its clinical trials in Mexico to help reduce costs and accelerate the opportunities for commercialization outside the US.

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2011, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.

Contact Information